PLA2G7 Antibody

• Catalog Number: orb1262035
• Category: Antibodies
• Description: PLA2G7 Antibody
• Species/Host: Rabbit
• Clonality: Polyclonal
• Tested applications: FC, IHC-P, WB
• Reactivity: Human
• Isotype: Rabbit Ig
• Immunogen: This PLA2G7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 200-228 amino acids from the Central region of human PLA2G7.
• Antibody Type: Primary Antibody
• Concentration: batch dependent
• Form/Appearance: Liquid
• Conjugation: Unconjugated
• MW: 50 kDa
• Target: PLA2G7
• UniProt ID: Q13093
• NCBI: Q13093
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Buffer/Preservatives: Supplied in PBS with 0.09% (W/V) sodium azide.
• Alternative names: Platelet-activating factor acetylhydrolase, PAF ac
• Note: For research use only
• Application notes: For FACS starting dilution is: 1:25For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:10~50
• Expiration Date: 12 months from date of receipt.

Overlay histogram showing HL-60 cells stained with Antibody (green line). The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (1:25 dilution) for 60 min at 37°C. The secondary antibody used was Goat-Anti-Rabbit IgG, Conjugated Highly Cross-Adsorbed at 1/200 dilution for 40 min at 37°C. Isotype control antibody (blue line) was rabbit IgG (1ug/1x10^6 cells) used under the same conditions. Acquisition of > 10000 events was performed.

Western Blot at 1:2000 dilution Lane 1: human liver lysate Lane 2: human lung lysate Lane 3: human spleen lysate Lane 4: human plasma lysate Lysates/proteins at 20 ug per lane.

Western blot analysis of PLA2G7 Antibody in HL-60 cell line lysates (35 ug/lane)

PLA2G7 Antibody IHC analysis in formalin fixed and paraffin embedded tonsil followed by peroxidase conjugation of the secondary antibody and DAB staining.